CN Patent

CN111298122A — 用于治疗小细胞肺癌的药物组合物及其应用

Assigned to Harbin University of Commerce · Expires 2020-06-19 · 6y expired

What this patent protects

本发明涉及一种用于治疗小细胞肺癌的药物组合物及其应用，属于药物领域。其包括lurbinectedin和选择性NA再摄取抑制剂。所述药物组合物中的lurbinectedin和选择性NA再摄取抑制剂的质量比为1:0.01‑1。

USPTO Abstract

本发明涉及一种用于治疗小细胞肺癌的药物组合物及其应用，属于药物领域。其包括lurbinectedin和选择性NA再摄取抑制剂。所述药物组合物中的lurbinectedin和选择性NA再摄取抑制剂的质量比为1:0.01‑1。

Drugs covered by this patent

Patent Metadata

Patent number
CN111298122A
Jurisdiction
CN
Classification
—
Expires
2020-06-19
Drug substance claim
No
Drug product claim
No
Assignee
Harbin University of Commerce
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.